Exalenz Bioscience Ltd.

Exalenz Bioscience Ltd. is an Israeli biotechnology company focused on developing and commercializing non-invasive diagnostic medical devices for gastrointestinal and liver conditions. The company utilizes advanced technology to analyze changes in a patient's exhaled breath, providing vital diagnostic information that helps medical specialists identify and manage digestive and liver diseases. The flagship product, the BreathID System, is a mobile diagnostic platform designed for assessing and monitoring functional diseases of the liver and gastrointestinal tract. This system offers a convenient alternative to traditional diagnostic methods and is particularly effective for H. pylori urea breath testing, which is essential for diagnosing gastrointestinal infections. Exalenz collaborates with clinical and industrial partners globally to enhance its diagnostic technologies and expand their applications. Exalenz has a diverse market presence, generating significant revenue in the United States, Israel, and other international markets. In 2020, the company was acquired by Meridian Bioscience, integrating its BreathID Systems into Meridian’s Diagnostics business unit to broaden the reach of its innovative testing solutions.

• Employees 25
• Founded 2006